New Therapeutics Options in HER2-Positive Breast Cancer

New York, USA, Oct. 12, 2022 (GLOBE NEWSWIRE) — New Therapeutics Options in HER2-Positive Breast Cancer Pipeline as 60+ Key Companies are Working on Drug Profiles | DelveInsight

The prevalence of HER2-Positive Breast Cancer has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing prevalence of breast cancer and its recurrence. The Companies developing the potential therapies in the last stage of development include Genentech, Ambrx ,Innate Pharma and several others.

DelveInsight’s ‘HER2-Positive Breast Cancer Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline HER2-positive breast cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the HER2-positive breast cancer pipeline domain.

Key Takeaways from the HER2-Positive Breast Cancer Pipeline Report

• DelveInsight’s HER2-positive breast cancer pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for HER2-positive breast cancer treatment. 
• Key HER2-positive breast cancer companies such as Ambrx, Alteogen, Suzhou Zanrong Pharma Limited, AstraZeneca, Shanghai Henlius Biotech, GeneQuantum Healthcare (Suzhou) Co., Ltd., Klus Pharma Inc., Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, Seagen Inc., CSPC ZhongQi Pharmaceutical Technology Co., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Shanghai Miracogen Inc., Roche Pharma AG, Dizal Pharmaceuticals, Greenwich LifeSciences, Zymeworks Inc., Pieris Pharmaceuticals, Inc., Orum Therapeutics, RemeGen Co., Ltd., Mersana Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Tianjin Hemay Biotech, Precirix, Zymeworks Inc., Menarini Group, Cadila Healthcare Limited, Merus N.V., Genentech, Shanghai PerHum Therapeutics Co., Ltd., ALX Oncology, Zymeworks Inc.,…